[1] Bystrom LM, Guzman ML, Rivella S. Iron and reactive oxygen species: friends or foes of cancer cells?. Antioxid Redox Sign , 2014, 20(12): 1917-1924.
[2] Estevão IF, Junior PP, Bonini-Domingos CR. Serum ferritin and transferrin saturation levels in β 0 and β + thalassemia patients. Genet Mol Res , 2011, 10(2): 632-639.
[3] Galano A, Medina ME, Tan DX, Reiter RJ. Melatonin and its metabolites as copper chelating agents and their role in inhibiting oxidative stress: a physicochemical analysis. J Pineal Res , 2015, 58(1): 107-116.
[4] McKay PJ, Murphy JA, Cameron S, Burnett AK, Campbell M, Tansey P, Franklin IM. Iron overload and liver dysfunction after allogeneic or autologous bone marrow transplantation. Bone Marrow Transplant , 1996, 17(1): 63-66.
[5] Ali S, Pimentel JD, Munoz J, Shah V, McKinnon R, Divine G, Janakiraman N. Iron overload in allogeneic hematopoietic stem cell transplant recipients. Arch Pathol Laborat Med , 2012, 136(5): 532-538.
[6] Trottier BJ, Burns LJ, DeFor TE, Cooley S, Majhail NS. Association of iron overload with allogeneic hematopoietic cell transplantation outcomes: a prospective cohort study using R2-MRI-measured liver iron content. Blood , 2013, 122(9): 1678-1684.
[7] Gordon LI, Brown SG, Tallman MS, Rademaker AW, Weitzman SA, Lazarus HM, Kelley CH, Mangan C, Rubin H, Fox RM, Creger RJ, Winter JN. Sequential changes in serum iron and ferritin in patients undergoing high-dose chemotherapy and radiation with autologous bone marrow transplantation: Possible implications for treatment related toxicity. Free Rad Biol Med , 1995, 18(3): 383-389.
[8] Meyer SC, O’Meara A, Buser AS, Tichelli A, Passweg JR, Stern M. Prognostic impact of posttransplantation iron overload after allogeneic stem cell transplantation. Biol Blood Marrow Tr , 2013, 19(3): 440-444.
[9] Busca A, Dellacasa C, Pecoraro C. Iron overload in patients receiving allogeneic hematopoietic stem cell transplantation. Global J Hematol Blo , 2014, 1: 6-17.
[10] Sivgin S, Eser B. The management of iron overload in allogeneic hematopoietic stem cell transplant (alloHSCT) recipients: Where do we stand?. Ann Hematol , 2013, 92(5): 577-586.
[11] Muckenthaler MU. Red Cells, Iron, & Erythropoiesis: How mutant HFE causes hereditary hemochromatosis. Blood , 2014, 124(8): 1212.
[12] de Witte T. The role of iron in patients after bone marrow transplantation. Blood Rev , 2008, 22(Suppl. 2): S22-S28.
[13] Chua K, Fung E, Micewicz ED, Ganz T, Nemeth E, Ruchala P. Small cyclic agonists of iron regulatory hormone hepcidin. Bioorg Med Chem Lett , 2015, doi:
10.1016/j.bmcl.2015.03.012.
[14] Sucak GT, Yaşar DG, Yegin ZA, Ergün MA, Özkurt ZN, Akı ŞZ, Güntekin S. The prognostic role of hemochromatosis H63D allele in allogeneic hematopoietic stem cell transplantation. Ann Hematol , 2012, 91(8): 1281-1287.
[15] Kaczorowska-Hac B, Szalewska M, Niedzwiecki M, Adamkiewicz-Drozynska E, Milosz E. Iron overload in two children after allogeneic hematopoietic SCT with concomitant HFE p.s65cgene mutation. J Blood Lymph , 2014, 4(1): 1000117.
[16] Finch C. Regulators of iron balance in humans. Blood , 1994, 84(6): 1697-1702.
[17] Liu QD, Davidoff O, Niss K, Haase VH. Hypoxia-inducible factor regulates hepcidin via erythropoietin-induced erythropoiesis. J Clin Invest , 2012, 122(12): 4635.
[18] Tanno T, Bhanu NV, Oneal PA, Goh SH, Staker P, Lee YT, Moroney JW, Reed CH, Luban NLC, Wang RH, Eling TE, Childs R, Ganz T, Leitman SF, Fucharoen S, Miller JL. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med , 2007, 13(9): 1096-1101.
[19] Tanno T, Porayette P, Sripichai O, Noh SJ, Byrnes C, Bhupatiraju A, Lee YT, Goodnough JB, Harandi O, Ganz T, Paulson RF, Miller JL. Identi
